glp-1 serotonin glp 1 and schizophrenia Interaction of serotonin/GLP-1 circuitry in a dual preclinical model for psychiatric disorders metabolic dysfunction Receptor Agonists Improve Metabolic – GLP-1 and the Degenerating Brain:

I say, let the data leads us to enlightenment

Observed responses in research settings are generally reported as mild and may include: Temporary injection-site irritation Redness or warmth sensations Skin-sensitivity variability Temporary blue-tinted discoloration beneath the administration area Localized irritation depending on dosage range, concentration, administration frequency, protocol duration, and individual sensitivity Research protocols commonly investigate daily administration ranges between: 12mg daily in standard research settings Up to 3mg daily in more advanced experimental protocols GHK-Cu is frequently explored in continuous or maintenance-style research structures and does not always require strict cycling protocols in moderate-dose experimental models

From a functional medicine standpoint: Topical copper peptides are ideal for localized, consistent, preventative skin longevity Injectable copper peptides are reserved for select patients seeking more aggressive or systemic regenerative support For this reason, many patients begin with topical copper peptides and only consider injectable options when clinically appropriate

So, this seemed like a good experiment to see if something unlocks